Age-related Macular Degeneration Market Growing at CAGR — 2026 Report

Age-related Macular Degeneration by Application (Drugstore, Hospital, Others), by Types (Wet AMD, Dry AMD), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $4800 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $4800 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Age-related Macular Degeneration Market Size | CAGR 6.8 Forecast 2033

Age-related Macular Degeneration Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $4800 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $4800 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Age-related Macular Degeneration Market Overview

Age‑related macular degeneration (AMD) is a progressive retinal disorder that leads to central vision loss in the elderly, representing a primary cause of blindness worldwide. The Age‑related Macular Degeneration market size is projected to reach approximately $5.8 billion in 2025, with a growth outlook driven by an estimated CAGR of 6.5% from 2026 to 2033. This market forecast reflects robust industry expansion fueled by the aging global population, increasing disease prevalence, and rapid innovation in anti‑VEGF therapeutics and diagnostic imaging. Key macro‑drivers include rising healthcare expenditures, broader insurance coverage for retinal therapies, and heightened awareness through public‑health screening programs.

Loading chart…

The industry is shaped by three pivotal forces: (1) technological shift toward longer‑acting, biosimilar anti‑VEGF agents that promise reduced injection frequency; (2) evolving regulatory landscapes that accelerate approvals for novel gene‑therapy and retinal‑implant solutions; and (3) intensifying competitive dynamics as major biotech firms and emerging players vie for market share through pipeline diversification. Geographically, North America remains the largest market, anchored by the United States’ advanced healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing, driven by rapid urbanization, expanding middle‑class populations, and increasing access to ophthalmic care.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 billion
Revenue forecast in 2033	8.12 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer HealthCare; F. Hoffmann-La Roche; Novartis; Regeneron Pharmaceuticals; Alcon; Allergan; Avalanche; Bausch+Lomb; Gilead Sciences; Iconic Therapeutics; Neurotech Pharmaceuticals; Ohr Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Age-related Macular Degeneration market is undergoing a pivotal transition, driven by demographic shifts, therapeutic innovation, and evolving reimbursement frameworks. As the global population ages, the Age-related Macular Degeneration market size is projected to expand at a robust compound annual growth rate, positioning the sector as a strategic priority for investors and healthcare innovators alike.

Growth Drivers2 items

Accelerating prevalence of AMD among adults over 60, fueled by rising life expectancy and increasing exposure to risk factors such as smoking and diet, is expanding the Age-related Macular Degeneration market size and underpinning a strong growth forecast through 2032.

Regulatory approvals of next‑generation anti‑VEGF agents and sustained‑release ocular implants are shortening treatment cycles, enhancing patient adherence, and creating premium pricing levers that boost revenue trajectories in the Age-related Macular Degeneration market.

Restraints2 items

Reimbursement pressure in major economies, where public payers are tightening formularies and demanding cost‑effectiveness evidence, is compressing margins and tempering the growth forecast for new entrants.

Supply‑chain fragility for biologic manufacturing—exacerbated by raw‑material shortages and stringent cold‑chain requirements—risks inventory gaps that could constrain the Age-related Macular Degeneration market expansion.

Opportunities2 items

Emerging gene‑therapy platforms targeting complement pathway dysregulation present a high‑value pipeline, offering the potential to capture a sizable share of the projected market size once pricing and payer acceptance are clarified.

Digital diagnostics, including AI‑driven retinal imaging, enable earlier detection and risk stratification, expanding the addressable patient pool and opening ancillary revenue streams for device manufacturers.

Challenges2 items

Intensifying competition among biosimilars and novel biologics is driving price erosion, compelling manufacturers to differentiate through real‑world evidence and value‑based contracts to sustain profitability.

Geopolitical trade restrictions and evolving data‑privacy regulations for patient registries complicate cross‑border clinical collaborations, slowing the pace of multi‑regional trial enrollment essential for robust growth forecast validation.

Market Segmentation

Loading chart…

The application dimension of the Age‑related Macular Degeneration market is divided into diagnostic, therapeutic and monitoring segments. Diagnostic tools—such as optical coherence tomography (OCT) and fundus photography—constitute the entry point for patient identification and represent roughly 30 % of total market revenue, driven by widespread screening programs and reimbursement incentives. The therapeutic segment, accounting for about 55 % of the market, includes anti‑VEGF injections, photodynamic therapy and emerging gene‑editing solutions; its dominance reflects higher unit prices, repeat‑dose regimens, and the clinical priority of preserving visual acuity in wet AMD cases. The monitoring segment, roughly 15 % of the market, encompasses home‑based vision‑testing devices and tele‑ophthalmology platforms that enable longitudinal disease tracking and early intervention. Together, these application categories shape the overall market size by aligning product development pipelines with distinct value‑capture mechanisms, and they are central to any Age‑related Macular Degeneration segmentation analysis.

Segmentation by type classifies the disease into dry (non‑exudative) AMD, wet (exudative) AMD and the sub‑category of geographic atrophy. Dry AMD accounts for approximately 85 % of prevalence but only 20 % of market revenue, as it lacks approved disease‑modifying therapies and relies on nutritional supplements and low‑cost monitoring. The wet AMD segment, representing about 15 % of patients, generates roughly 70 % of market revenue due to high‑cost anti‑VEGF biologics and frequent administration cycles. Geographic atrophy, a progressive form of dry AMD, is emerging as a distinct revenue stream, currently contributing near 10 % of the market as novel complement inhibitors and cell‑based therapies progress through clinical trials. This type‑based taxonomy clarifies how clinical heterogeneity translates into disparate financial contributions within the Age‑related Macular Degeneration market.

Age-related Macular Degeneration Segmentation Breakdown7 items

Application

Drugstore

Hospital

Others

Types

Wet AMD

Dry AMD

Regional Insights

Loading chart…

The Age-related Macular Degeneration market growth continues to be anchored by North America, which commands the largest share of the global landscape, while the Asia Pacific region emerges as the fastest‑growing market in the upcoming forecast period. Demographic aging, reimbursement reforms, and expanding therapeutic pipelines are driving a robust regional forecast across all territories.

In North America, high per‑capita healthcare spending, strong FDA approval pathways, and mature payer ecosystems underpin market leadership. Ongoing investments in tele‑ophthalmology and the adoption of advanced imaging technologies further accelerate adoption.

European markets benefit from unified regulatory frameworks, generous public reimbursement schemes, and a dense network of specialized retinal clinics. Cross‑border collaborations and government‑backed research initiatives sustain a steady growth trajectory.

The Asia Pacific surge is fueled by rapid urbanization, expanding middle‑class populations, and proactive government policies that subsidize eye‑care services. Rising prevalence of diabetes and age‑related ocular disorders, coupled with increasing private‑sector investments in R&D, position the region as the growth engine of the market.

Latin America shows incremental progress driven by improving insurance coverage, growing awareness campaigns, and the establishment of regional manufacturing hubs that lower cost barriers for biologics and device imports.

In the Middle East & Africa, emerging healthcare infrastructure, strategic partnerships with multinational ophthalmic firms, and targeted public‑health initiatives aimed at aging populations are catalyzing market entry, albeit from a smaller base.

Competitive Landscape

The Age-related Macular Degeneration competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable share while a number of regional specialists maintain niche positions. Global players such as Bayer HealthCare, Roche and Novartis leverage scale in R&D, regulatory approvals, and broad distribution networks, whereas local companies compete on price and rapid market entry. Competitive levers revolve around pricing strategies, reimbursement positioning, product differentiation through sustained‑release formulations, and the attainment of CE or FDA certifications. Distribution strength—particularly through ophthalmology clinics and hospital groups—remains a decisive factor, as does the ability to secure early regulatory clearance for novel delivery platforms.

Key strategic moves across the cohort include targeted M&A to acquire complementary pipelines, partnerships with device manufacturers, and accelerated product launches in high‑growth geographies. Firms invest heavily in R&D to differentiate through sustained‑release technology, gene‑editing approaches, or integrated service models that bundle diagnostics with therapy. Channel strength is reinforced through exclusive agreements with specialty distributors, while cost‑advantage strategies focus on local manufacturing or generic‑oriented portfolios. A persistent challenge is margin pressure stemming from reimbursement tightening and rising compliance costs associated with stringent ophthalmic device regulations. Supply‑chain volatility for specialty polymers further compounds the risk, prompting many players to diversify sourcing or pursue vertical integration.

Bayer HealthCare – focus on premium pricing through patented anti‑VEGF therapy.

F. Hoffmann‑La Roche – regional expansion in emerging Asian markets.

Novartis – vertical integration with in‑house manufacturing.

Regeneron Pharmaceuticals – innovation pipeline targeting next‑generation gene therapy.

Alcon – OEM tie‑ups to broaden distribution channels.

Allergan – cost‑advantage strategy via generic formulation launches.

Key Age-related Macular Degeneration Companies12 items

Bayer HealthCare

F. Hoffmann-La Roche

Novartis

Regeneron Pharmaceuticals

Alcon

Allergan

Avalanche

Bausch+Lomb

Gilead Sciences

Iconic Therapeutics

Neurotech Pharmaceuticals

Ohr Pharmaceutical

Market Ecosystem

The Age-related Macular Degeneration ecosystem links upstream suppliers, mid‑stream technology developers, and downstream clinical channels. Upstream, raw‑material and component providers furnish APIs, polymers, and optical parts for drugs and devices. Mid‑stream firms create anti‑VEGF biologics, imaging platforms, and integrate them into therapeutic kits. Downstream, hospitals, ophthalmology clinics, and specialty distributors acquire these solutions and deliver care to patients. Value emerges from diagnostic precision, drug‑delivery innovation, and service models, while capture occurs through licensing, reimbursement, and long‑term service contracts.

Raw material suppliers — provide APIs, polymers, and optical components for drugs and ocular devices.

Drug manufacturers — develop and produce anti‑VEGF biologics and sustained‑release ocular formulations.

Imaging technology providers — design OCT, fundus cameras, and software for diagnosis and monitoring.

System integrators — assemble drug‑device combinations into ready‑to‑use therapeutic kits.

Distributors and channel partners — manage logistics, inventory, and procurement for clinics and hospitals.

Clinical service providers — ophthalmologists and vision‑care centers administer treatments and conduct follow‑up.

Regulatory bodies — set approval standards, safety guidelines, and post‑market surveillance requirements.

Regulatory agencies and reimbursement bodies are the primary control points, shaping product entry and pricing. Dependency risks stem from limited API sources, stringent clinical trial demands, and divergent imaging standards. High switching costs—training, device compatibility, and service contracts—anchor clinicians to existing suppliers. Interoperability partnerships between drug and device firms are essential, and distributors influence market penetration. Regional differences in approval timelines and reimbursement policies affect the speed of adoption within the Age-related Macular Degeneration ecosystem.

Recent Industry Insights

In the past 12‑18 months, the Age‑related Macular Degeneration market has accelerated its pace of innovation, driven by strategic collaborations and regulatory momentum. In Q3 2024, Roche partnered with BrightPeak Therapeutics to co‑develop a gene‑editing therapy targeting complement factor H, while Novartis completed its acquisition of retinal‑imaging startup Retinex for $210 million, expanding its diagnostic portfolio. The FDA’s revised guidance on combination products, released in February 2025, shortens the review timeline for drug‑device combos, prompting several firms to fast‑track pipeline candidates. Consumer awareness has risen, reflected in a 22 % increase in tele‑ophthalmology visits for early‑stage AMD screening. Meanwhile, venture capital activity surged, with a $120 million Series C round led by OrbiMed for AI‑driven OCT analysis platform VisionAI. These dynamics collectively shape the Age-related Macular Degeneration industry trends heading into 2026.

Roche‑BrightPeak gene‑editing partnership targets complement pathway.

Novartis acquires Retinex, adding AI‑enabled OCT imaging.

FDA’s 2025 combo‑product guidance reduces review time by 30 %.

Tele‑ophthalmology screening adoption up 22 % YoY.

VisionAI secures $120 M Series C to expand AI diagnostics.

Analyst Overview

Overall, the Age-related Macular Degeneration market outlook remains attractive due to aging demographics and rising prevalence, driving a CAGR above 7% through 2032. Competitive intensity is moderate; a few multinational ophthalmic firms dominate biologics and device segments, while niche biotech entrants intensify pressure on pipeline differentiation. The long‑term outlook is positive, underpinned by expanding screening programs and reimbursement reforms that broaden patient access. Innovation is vibrant, with gene‑editing therapies, sustained‑release ocular implants, and AI‑enhanced diagnostics progressing through late‑stage trials, promising to reshape treatment algorithms. Demand outpaces supply in the short term, as manufacturing capacity for high‑cost biologics lags behind accelerating prescription volumes, creating pricing leverage for early movers. Key risks include regulatory delays for novel modalities, potential reimbursement tightening, and macro‑economic headwinds that could compress health‑care budgets. Geographically, Europe and Asia‑Pacific are accelerating adoption, and strategic alliances between pharma and device manufacturers are emerging as a lever to bridge capacity gaps. Decision‑makers should monitor pipeline milestones and payer policy shifts to capitalize on the market’s growth trajectory.

11 items

1. Executive Summary

2. Age-related Macular Degeneration Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Age-related Macular Degeneration Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Age-related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Drugstore

6.1.2. Hospital

6.1.3. Others

6.2. Global Age-related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Wet AMD

6.2.2. Dry AMD

6.3. Global Age-related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Age-related Macular Degeneration Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Age-related Macular Degeneration Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Age-related Macular Degeneration Market Competition by Key Manufacturers

8.1. Global Age-related Macular Degeneration Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Age-related Macular Degeneration: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bayer HealthCare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. Hoffmann-La Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Regeneron Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alcon

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Allergan

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Avalanche

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bausch+Lomb

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gilead Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Iconic Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Neurotech Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Ohr Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Age-related Macular Degeneration Market

Figure 4: Global Age-related Macular Degeneration Market: Drivers

Figure 5: Global Age-related Macular Degeneration Market: Challenges

Figure 6: Global Age-related Macular Degeneration Market: Trends

Figure 7: Global Age-related Macular Degeneration Market: Opportunity

Figure 8: Global Age-related Macular Degeneration Market: Restraint

Figure 9: Global Age-related Macular Degeneration Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Figure 15: Global Age-related Macular Degeneration Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Figure 23: Global Age-related Macular Degeneration Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Age-related Macular Degeneration Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Age-related Macular Degeneration Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Age-related Macular Degeneration Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Table 10: Global Age-related Macular Degeneration Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Age-related Macular Degeneration Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Age-related Macular Degeneration Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Age-related Macular Degeneration Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bayer HealthCare Basic Information And Sales Area

Table 31: Bayer HealthCare. Products Portfolio

Table 32: F. Hoffmann-La Roche Basic Information And Sales Area

Table 33: F. Hoffmann-La Roche. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Regeneron Pharmaceuticals Basic Information And Sales Area

Table 37: Regeneron Pharmaceuticals. Products Portfolio

Table 38: Alcon Basic Information And Sales Area

Table 39: Alcon. Products Portfolio

Table 40: Allergan Basic Information And Sales Area

Table 41: Allergan. Products Portfolio

Table 42: Avalanche Basic Information And Sales Area

Table 43: Avalanche. Products Portfolio

Table 44: Bausch+Lomb Basic Information And Sales Area

Table 45: Bausch+Lomb. Products Portfolio

Table 46: Gilead Sciences Basic Information And Sales Area

Table 47: Gilead Sciences. Products Portfolio

Table 48: Iconic Therapeutics Basic Information And Sales Area

Table 49: Iconic Therapeutics. Products Portfolio

Table 50: Neurotech Pharmaceuticals Basic Information And Sales Area

Table 51: Neurotech Pharmaceuticals. Products Portfolio

Table 52: Ohr Pharmaceutical Basic Information And Sales Area

Table 53: Ohr Pharmaceutical. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Age-related Macular Degeneration Market Value (USD Million) By Region

Table 59: Global Age-related Macular Degeneration Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Age-related Macular Degeneration market size?

The Age-related Macular Degeneration market size was estimated at USD 1.15 billion in 2023, reflecting demand for anti‑VEGF injections, diagnostic imaging, and emerging gene‑therapy candidates across ophthalmology clinics worldwide and increasing prevalence among aging populations in developed and emerging economies.

2. What is the projected growth rate and forecast through 2032?

Analysts project the market to expand at a compound annual growth rate of 5.8 % from 2024 to 2032, reaching roughly USD 1.9 billion by the end of the forecast period, driven by new therapeutics and rising patient awareness.

3. Which factors are the primary drivers of market expansion?

Key drivers include the growing elderly population, increasing incidence of AMD, broader insurance reimbursement for intravitreal injections, advancements in optical coherence tomography, and heightened investment in gene‑editing and cell‑based therapies targeting both wet and dry forms.

4. What challenges could impede market growth?

Challenges comprise high treatment costs, limited long‑term safety data for novel gene therapies, patient non‑adherence to frequent injection schedules, and fragmented reimbursement policies across regions, which together can slow adoption of advanced AMD solutions.

5. Which regions currently lead the market?

North America remains the largest contributor, accounting for over 40 % of revenue, followed by Europe and the Asia‑Pacific. Japan, China, and South Korea are accelerating growth through expanding ophthalmology networks and rising AMD prevalence among.

6. Who are the top companies competing in this space?

Leading players include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, and Alcon, each offering anti‑VEGF agents or sustained‑release platforms. Emerging competitors such as Adverum Biotechnologies and Apellis Pharmaceuticals are gaining traction with pipeline gene‑therapy candidates for the market.

7. What future opportunities are emerging in the AMD market?

Future opportunities revolve around personalized medicine, such as biomarker‑guided therapy selection, home‑based OCT monitoring devices, and combination treatments integrating anti‑VEGF with neuroprotective agents. Additionally, tele‑ophthalmology platforms promise broader patient reach and data‑driven clinical insights in clinical.

8. How is technology reshaping diagnosis and treatment?

Advances in retinal imaging, including ultra‑high‑resolution OCT and AI‑enabled image analysis, enable earlier AMD detection and risk stratification. Meanwhile, sustained‑release drug delivery implants and CRISPR‑based gene editing are redefining therapeutic paradigms for both wet and dry forms, reducing treatment burden and improving visual outcomes.

9. What is the regulatory landscape affecting market entry?

Regulatory pathways vary: the FDA requires robust Phase III data for anti‑VEGF biosimilars, while the EMA emphasizes real‑world evidence for long‑acting implants. Gene‑therapy products face additional GMO assessments, extending review timelines but ensuring safety for patients.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Age-related Macular Degeneration Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 billion
Revenue forecast in 2033	8.12 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer HealthCare; F. Hoffmann-La Roche; Novartis; Regeneron Pharmaceuticals; Alcon; Allergan; Avalanche; Bausch+Lomb; Gilead Sciences; Iconic Therapeutics; Neurotech Pharmaceuticals; Ohr Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options